Samsung BiologicsLtd Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Samsung BiologicsLtd heeft een totaal eigen vermogen van ₩10,328.3B en een totale schuld van ₩1,468.4B, wat de schuld-eigenvermogensverhouding op 14.2% brengt. De totale activa en totale passiva bedragen respectievelijk ₩16,342.9B en ₩6,014.5B. De EBIT Samsung BiologicsLtd is ₩1,324.3B waardoor de rentedekking -91.7 is. Het heeft contanten en kortetermijnbeleggingen van ₩1,568.6B.

Belangrijke informatie

14.2%

Verhouding schuld/eigen vermogen

₩1.47t

Schuld

Rente dekkingsratio	-91.7x
Contant	₩1.57t
Aandelen	₩10.33t
Totaal verplichtingen	₩6.01t
Totaal activa	₩16.34t

Recente financiële gezondheidsupdates

These 4 Measures Indicate That Samsung BiologicsLtd (KRX:207940) Is Using Debt Reasonably Well

Sep 09

Does Samsung BiologicsLtd (KRX:207940) Have A Healthy Balance Sheet?

May 27

These 4 Measures Indicate That Samsung BiologicsLtd (KRX:207940) Is Using Debt Reasonably Well

Jan 18

Recent updates

These 4 Measures Indicate That Samsung BiologicsLtd (KRX:207940) Is Using Debt Reasonably Well

Sep 09

Samsung Biologics Co.,Ltd.'s (KRX:207940) 26% Share Price Surge Not Quite Adding Up

Jul 29

These 4 Measures Indicate That Samsung BiologicsLtd (KRX:207940) Is Using Debt Reasonably Well

Jan 18

What Kind Of Shareholders Own Samsung Biologics Co.,Ltd. (KRX:207940)?

Dec 28

How Much Is Samsung Biologics Co.,Ltd. (KRX:207940) CEO Getting Paid?

Dec 08

Did You Miss Samsung BiologicsLtd's (KRX:207940) Impressive 112% Share Price Gain?

Nov 18

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( ₩5,431.4B ) A207940 } overtreffen de korte termijn passiva ( ₩4,034.1B ).

Langlopende schulden: De kortetermijnactiva A207940 ( ₩5,431.4B ) overtreffen de langetermijnschulden ( ₩1,980.4B ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: A207940 heeft meer geld in kas dan de totale schuld.

Schuld verminderen: De schuld/eigen vermogen-ratio van A207940 is de afgelopen 5 jaar gedaald van 19.8% naar 14.2%.

Schuldendekking: De schuld van A207940 wordt goed gedekt door de operationele kasstroom ( 112.6% ).

Rentedekking: A207940 verdient meer rente dan het betaalt, dus de dekking van rentebetalingen is geen probleem.

Samsung BiologicsLtd Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Belangrijke informatie

Recente financiële gezondheidsupdates

These 4 Measures Indicate That Samsung BiologicsLtd (KRX:207940) Is Using Debt Reasonably Well

Does Samsung BiologicsLtd (KRX:207940) Have A Healthy Balance Sheet?

These 4 Measures Indicate That Samsung BiologicsLtd (KRX:207940) Is Using Debt Reasonably Well

Recent updates

Samsung Biologics Launches High-Concentration Formulation Platform to Accelerate High-Dose Drug Development

These 4 Measures Indicate That Samsung BiologicsLtd (KRX:207940) Is Using Debt Reasonably Well

Samsung Biologics Co.,Ltd.'s (KRX:207940) 26% Share Price Surge Not Quite Adding Up

Samsung Biologics Co.,Ltd. to Report First Half, 2024 Results on Jul 24, 2024

Does Samsung BiologicsLtd (KRX:207940) Have A Healthy Balance Sheet?

Insufficient new directors

What Samsung Biologics Co.,Ltd.'s (KRX:207940) P/E Is Not Telling You

Samsung Biologics Co.,Ltd. to Report Q1, 2024 Results on Apr 24, 2024

Full year 2023 earnings released: EPS: ₩12,051 (vs ₩11,442 in FY 2022)

Samsung Biologics Co.,Ltd., Annual General Meeting, Mar 15, 2024

Samsung Biologics Co.,Ltd., Annual General Meeting, Mar 15, 2024

Samsung Biologics Co.,Ltd. to Report Fiscal Year 2023 Final Results on Jan 24, 2024

Samsung Biologics Co.,Ltd. to Report Q3, 2023 Results on Oct 25, 2023

Samsung Biologics Announces Executive Appointments

Samsung Biologics Co.,Ltd. to Report Q2, 2023 Results on Jul 26, 2023

First quarter 2023 earnings released: EPS: ₩1,992 (vs ₩2,221 in 1Q 2022)

Consensus revenue estimates increase by 12%

Third quarter 2022 earnings released: EPS: ₩1,815 (vs ₩1,992 in 3Q 2021)

Consensus revenue estimates increase by 16%

Second quarter 2022 earnings released: EPS: ₩2,160 (vs ₩1,837 in 2Q 2021)

GreenLight Biosciences and Samsung Biologics Completes First Commercial-Scale Engineering Run for mRNA Covid-19 Vaccine

High number of new directors

Consensus EPS estimates increase by 13%

High number of new directors

First quarter 2022 earnings: Revenues exceed analyst expectations

Samsung Biologics Co.,Ltd. (KOSE:A207940) completed the acquisition of the remaining 49.9% stake in Samsungbioepis Co,.Ltd from Biogen Inc. (NasdaqGS:BIIB).

Samsung Biologics Co.,Ltd., Annual General Meeting, Mar 29, 2022

Samsung Biologics Co.,Ltd. (KOSE:A207940) reached an agreement to acquire 49.9% stake in Samsungbioepis Co,.Ltd from Biogen Inc. (NasdaqGS:BIIB) for $2.3 billion.

Third quarter 2021 earnings released: EPS ₩1,992 (vs ₩848 in 3Q 2020)

Samsung Biologics showcases its newest CDO process platform, S-Cellerate™, at BPI 2021, offering expedited timeline to IND and BLA

Samsung Biologics Joins Frontier 1.5D Project as Part of 2050 Carbon Neutral Initiative

Second quarter 2021 earnings released: EPS ₩1,837 (vs ₩786 in 2Q 2020)

First quarter 2021 earnings released: EPS ₩922 (vs ₩554 in 1Q 2020)

Full year 2020 earnings released: EPS ₩3,642 (vs ₩3,067 in FY 2019)

With EPS Growth And More, Samsung BiologicsLtd (KRX:207940) Is Interesting

Samsung Biologics Co.,Ltd., Annual General Meeting, Mar 19, 2021

New 90-day low: ₩783,000

Samsung Biologics, National OncoVenture, and Eutilex Obtain IND Approval from FDA

Samsung Biologics Co.,Ltd. to Report Fiscal Year 2020 Results on Jan 26, 2021

These 4 Measures Indicate That Samsung BiologicsLtd (KRX:207940) Is Using Debt Reasonably Well

What Kind Of Shareholders Own Samsung Biologics Co.,Ltd. (KRX:207940)?

How Much Is Samsung Biologics Co.,Ltd. (KRX:207940) CEO Getting Paid?

New 90-day high: ₩825,000

Samsung Biologics Announces Strategic Manufacturing Partnership with Lilly to Accelerate Delivery of COVID-19 Antibody Treatments

Did You Miss Samsung BiologicsLtd's (KRX:207940) Impressive 112% Share Price Gain?

FibroGen, Inc. Enters into a Master Services Agreement with Samsung Biologics Co., Ltd

Samsung Biologics and Checkpoint Therapeutics Expand Manufacturing Partnership for Cosibelimab

Samsung Biologics Establishes Partnership with GeneQuantum Healthcare to Collaborate on ADC Development

New 90-day low: ₩658,000

Samsung Biologics Co.,Ltd. to Report Nine Months, 2020 Results on Oct 21, 2020

Samsung Biologics Signs Strategic Partnership with Kanaph Therapeutics to Develop Treatment for Retinal Diseases

New 90-day low: ₩705,000

Samsung Biologics and Astrazeneca Forge Strategic Manufacturing Partnership for Global Supply

Samsung Biologics Signs Development Agreement with Panolos for Solid Tumor Treatment

Price target raised to ₩843,438

New 90-day high - ₩843,000

Earnings released

Samsung Biologics Co.,Ltd. to Report First Half, 2020 Results on Jul 21, 2020

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Ontdek gezonde bedrijven